A study conducted by Laura Bukavina, MD, MPH, MSc, and colleagues published in JCO Oncology Practice investigated financial distress across genitourinary (GU) cancer survivors, with a focus on prostate, kidney, and bladder cancers. Researchers focused on the economic impact of disparities related to insurance coverage and its associations with the material, psychological, and behavioral elements of financial distress. They noted that financial distress included subjective difficulties faced by patients, including emotional and psychological struggles. ...
Prostate Cancer
Advertisement
Latest News
PSMA PET/CT can act as a better alternative to MRI, but research on second-generation PSMA PET radioligands is limited.
The FDA has accepted an NDA for TLX007-CDx, a cold kit for the preparation of PSMA-PET imaging for prostate cancer.
About 1 in 12 patients who undergo non-targeted prostate biopsy with a result of GGG 1 PC may have more aggressive cancer.
Darolutamide plus ADT provided a clinically meaningful increase in rPFS compared with placebo plus ADT.
Patients were sorted into groups based on modifiable lifestyle behaviors and genetic risk.
Abiraterone acetate, prednisone, and apalutamide is a common combination treatment for mCRPC.
Advertisement
Conference Coverage
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
![PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC](https://mumcdnstorage.blob.core.windows.net/guonc/2024/06/122-GUOnc_YouTube_Sartor_1280x720.jpg)
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
Advertisement
Advertisement
Latest News
The genetic basis of HER2 overexpression other than ERBB2 amplification in UC is not well understood.
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
ACSS2 Inhibition as a Therapeutic Strategy in ccRCC: Impacts on HIF-2α, Metabolism, and Tumor Growth
The group discusses how blocking ACSS2 may affect immune cells in the tumor microenvironment. 